Hideaki Matsuoka
Corporate Officer/Principal bij Astellas Venture Management LLC
Oorsprong van het eerstegraads netwerk van Hideaki Matsuoka
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Astellas Venture Management LLC
 Astellas Venture Management LLC Investment ManagersFinance Astellas Venture Management LLC (Astellas Venture Management) is a venture capital subsidiary of Astellas Pharma Inc founded in 2000. The firm is headquartered in San Francisco, California.
2
| Subsidiary | Investment Managers | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Hideaki Matsuoka via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| University of Massachusetts | College/University | Masters Business Admin | |
| ASTELLAS PHARMA INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Astellas Pharma US, Inc.
 Astellas Pharma US, Inc. Pharmaceuticals: MajorHealth Technology Astellas Pharma US, Inc. manufactures pharmaceutical products. It offers cardiology, dermatology, immunology, infectious diseases, and urology. The firm was founded in 2005 and is headquartered in Northbrook, IL. | Pharmaceuticals: Major | Director/Board Member | |
| Kyoto University | College/University | Graduate Degree | |
| Yamanouchi Pharma America, Inc. | Director/Board Member | ||
| Tokyo University of Science | College/University | Undergraduate Degree | |
Cleave Therapeutics, Inc.
 Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
Solu Therapeutics
 Solu Therapeutics Pharmaceuticals: MajorHealth Technology Solu Therapeutics is an American precision-medicine company focused on developing therapeutics to eliminate disease-driving cells in cancer, immunology, and autoimmunity. The company is located in the US. The company's proprietary cytotoxicity targeting chimera (cytac) platform and drug candidates, licensed from GSK, unlock antibody-intractable cell surface targets, providing the capability to develop next-generation medicines that harness the power of biologics with the vast target binding space of small molecules. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 6 |
| Japan | 4 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 4 |
Operationeel
| Director/Board Member | 4 |
| Private Equity Investor | 2 |
| Undergraduate Degree | 2 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sterkste connecties
| Insiders | |
|---|---|
| Satoshi Konagai | 6 |
| Tadayoshi Hirata | 4 |
- Beurs
- Insiders
- Hideaki Matsuoka
- Bedrijfsconnecties
